Related references
Note: Only part of the references are listed.Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
Jumin Huang et al.
GUT (2022)
Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
Kazuki Takada et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
Alice Indini et al.
CANCERS (2021)
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
A. Galvano et al.
ESMO OPEN (2021)
Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy
Xia Wu et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2021)
Peripheral T cell expansion predicts tumour infiltration and clinical response
Thomas D. Wu et al.
NATURE (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
Xiao-Xiao Peng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Daan P. Hurkmans et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
Small Nuclear RNAs (U1, U2, U5) in Tumor-Educated Platelets Are Downregulated and Act as Promising Biomarkers in Lung Cancer
Xiaohan Dong et al.
FRONTIERS IN ONCOLOGY (2020)
An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+T Cells is Dependent on IL-10 and Independent of BRAFV600EMutation in Melanoma Cell Lines
ShinLa Shu et al.
IMMUNOLOGICAL INVESTIGATIONS (2020)
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
Shumin Li et al.
FRONTIERS IN IMMUNOLOGY (2020)
Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells
Nina Guyon et al.
CELL DEATH & DISEASE (2020)
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
Valsamo Anagnostou et al.
CELL REPORTS MEDICINE (2020)
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies
Patrycja Pawlikowska et al.
JOURNAL OF THORACIC DISEASE (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small updates cell lung cancer patients treated with nivolumab
Julia Ouaknine Krief et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Ann Rita Halvorsen et al.
ACTA ONCOLOGICA (2018)
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
Marzia Del Re et al.
BRITISH JOURNAL OF CANCER (2018)
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
Tao Jiang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
A. Mitsuhashi et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
Aya Nakaya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Adrien Costantini et al.
ONCOIMMUNOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Resident memory T cells, critical components in tumor immunology
Fathia Mami-Chouaib et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The clinical utility of tumor mutational burden in non-small cell lung cancer
Laurent Greillier et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
Efimia Boutsikou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Nuray Akyuez et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Gut microbiota modulation of chemotherapy efficacy and toxicity
James L. Alexander et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance
Li-juan Chen et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis
Yanjun Hu et al.
ONCOTARGET (2017)
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu et al.
ONCOTARGET (2017)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer
Dan Liu et al.
BMC CANCER (2017)
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
L. Cabel et al.
ANNALS OF ONCOLOGY (2017)
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Benjamin M. Larimer et al.
CANCER RESEARCH (2017)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
A. S. Mansfield et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Circulating tumor cell clusters: What we know and what we expect (Review)
Yupeng Hong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Exosomes and tumor-mediated immune suppression
Theresa L. Whiteside
JOURNAL OF CLINICAL INVESTIGATION (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8
Lingling Xu et al.
ONCOTARGET (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo et al.
SCIENTIFIC REPORTS (2016)
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas
Sehui Kim et al.
EUROPEAN JOURNAL OF CANCER (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
microRnAs: an emerging paradigm in lung cancer chemoresistance
Srivatsava Naidu et al.
FRONTIERS IN MEDICINE (2015)
Prognostic Significance of MicroRNA-375 Downregulation in Solid Tumors: A Meta-Analysis
Yingjie Shao et al.
DISEASE MARKERS (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
Laura Muinelo-Romay et al.
CANCERS (2014)
Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis
Don Lynn Gibbons et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth A. Punnoose et al.
CLINICAL CANCER RESEARCH (2012)
Decreased Expression of MicroRNA-375 in Nonsmall Cell Lung Cancer and its Clinical Significance
Y. Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
Mary L. Disis
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity
Mona Skjelland et al.
ATHEROSCLEROSIS (2007)
Share Paper
